Drug Database
IN

infliximab (Anbaite / HS626 / HS 626)

✓ Approved

Zhejiang Hisun Pharmaceutical Co., Ltd. · TNF · 单克隆抗体

什么是 infliximab?

infliximab 是一种单克隆抗体,由Zhejiang Hisun Pharmaceutical Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Anbaite, HS626, HS 626
公司Zhejiang Hisun Pharmaceutical Co., Ltd.
药物类别单克隆抗体, 抗体
分子靶点TNF
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

infliximab 作用于 1 个分子靶点:

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

infliximab 针对 5 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

相关研究文献

PubMedAlimentary pharmacology & therapeutics2026-11-18

Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD-Is This the Time for Model Informed Precision Dosing? Authors' Reply.

Mohamedi Juma A JA, Liefferinckx Claire C, Dreesen Erwin E

PMID 43046898
阅读全文 →
PubMedJPGN reports2026-11-18

Novel pathogenic variant in haploinsufficiency of A20 with severe gastrointestinal effects and fulminant hepatic failure: A pediatric case series.

Blake Amanda A, Cheng Katherine K, Wen Kwun Wah KW, Byers Joshua J et al.

Haploinsufficiency of A20 (HA20) is a rare autoinflammatory disorder caused by heterozygous loss-of-function variants in tumor necrosis factor alpha-induced protein 3 (TNFAIP3), encoding a negative regulator of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling. We report two pediatric patients with a previously unreported novel pathogenic variant (p. Glu409*) in the zinc finger (ZnF) 1 domain, exhibiting markedly divergent phenotypes. Case 1 presented with very-early-onset inflammatory bowel disease (VEO-IBD) and autoimmune thyroiditis, requiring aggressive infliximab dose escalation. Case 2 developed fulminant hepatic failure requiring liver transplantation, followed by post-transplant complications including refractory rejection, recurrent infections, and post-transplant lymphoproliferative disorder. This represents the first known case of HA20 in solid organ transplantation. These cases underscore the importance of early genetic diagnosis in unexplained pediatric inflammatory disease and transplant rejection, as HA20 recognition may alter immunosuppressive strategies and guide therapies including cytokine blockade or Janus kinase (JAK) inhibition.

PMID 43048450
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Baseline TNF-α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease.

Kwon Yiyoung Y, Kim Eun Sil ES, Kim Yoon Zi YZ, Jeong Tae Jong TJ et al.

Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD. This prospective study included pediatric patients with moderate-to-severe CD treated with IFX. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses. Of the 160 enrolled patients, 15 (9.4%) were not included in the 1-year analysis, and 145 (90.6%) completed the 1-year follow-up. Body mass index (BMI)-adjusted TNF-α levels correlated with erythrocyte sedimentation rate (R = 0.22, p = 0.008) and fecal calprotectin (R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL-6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF-α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046). Higher baseline TNF-α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES-CD or anatomical disease phenotype. These findings suggest that baseline TNF-α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.

PMID 43042664
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Immune-epithelial coordination of barrier repair in inflammatory bowel disease: from cell survival to functional healing.

Wu Ben B, He Bin-Sheng BS

Epithelial repair in inflammatory bowel disease involves preservation of viable cells, coverage of wounds, renewal of epithelial populations and recovery of selective transport and secretion. These processes overlap, yet improvement in one does not establish completion of the others. This narrative review examines how immune signals influence these transitions and how experimental repair findings relate to patient outcomes. We first describe the junctional and mucus barrier and the distinction between physiological, endoscopic and histological measurements. We then examine epithelial death control, regenerative pathways and immune-derived signals using studies selected for compartment-specific perturbation, functional measurements or informative discrepancies between experimental and clinical findings. Interleukin-22 illustrates the importance of context: it promotes regeneration in several experimental systems, disrupts barrier function in a human colon chip, and has not yielded demonstrated efficacy as efmarodocokin alfa in a phase II ulcerative colitis trial. In one small infliximab study, paired measurements from nine patients showed an increase in epithelial resistance after treatment. Larger controlled studies are needed to establish how consistently functional recovery accompanies immune control. We organize the evidence around target engagement, epithelial response, barrier function and patient benefit, with example assays and common interpretive pitfalls for each. The resulting synthesis identifies the measurements needed to distinguish protection from repair and to test whether an epithelial effect adds value to effective immune therapy. Clinical studies must ultimately establish that a specified functional improvement is durable and beneficial to patients.

PMID 43041937
阅读全文 →
PubMedJournal of translational autoimmunity2026-11-15

Impact of infliximab combined with methotrexate on serum inflammatory and immunometabolic biomarkers in rheumatoid arthritis.

Al-Maslamani Bilal B, Soudi Sara S, Al-Ghazaly Zakariya Muayad ZM

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with metabolic reprogramming of immune cells. Although inflammatory cytokines have been extensively studied, the effects of disease-modifying therapies including methotrexate, infliximab and their combination on serum immunometabolic biomarkers remain incompletely understood. This cross-sectional study included newly diagnosed RA patients, patients receiving MTX monotherapy, patients receiving MTX plus infliximab, and healthy controls. Serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), lactate, citrate, and succinate dehydrogenase (SDH) activity were measured. Disease activity was evaluated using the Disease Activity Score in 28 joints (DAS28). Statistical analyses, hierarchical clustering, correlation and network analyses, principal component analysis (PCA), and exploratory structural equation modeling (SEM) were used to investigate immunometabolic relationships and treatment-associated changes. Newly diagnosed RA patients showed significantly elevated TNF-α, IL-10, lactate, SDH activity, TNF-α/IL-10 ratio, and DAS28, alongside reduced citrate levels compared with controls and treated patients. Combined MTX and infliximab therapy demonstrated the greatest improvement in inflammatory and metabolic biomarkers and the lowest disease activity. Multivariate analyses identified TNF-α, lactate, and DAS28 as major contributors to disease-associated variation, while citrate displayed an opposing metabolic pattern. Correlation and network analyses identified TNF-α as a central link between inflammation, metabolic remodeling, and disease severity. SEM suggested that treatment-associated reductions in TNF-α were related to decreased glycolytic activity, improved mitochondrial metabolism, and reduced disease activity. RA involves coordinated inflammatory and metabolic dysregulation. Combined MTX and infliximab therapy appears more effective than MTX alone in restoring immunometabolic balance.

PMID 43032676
阅读全文 →
PubMedACG case reports journal2026-11-15

Advanced Combination Therapy for Pediatric Isolated Upper Gastrointestinal Crohn's Disease.

Towbin Noah N, Huebner Thomas T, Arai Ronen R

Isolated upper gastrointestinal (UGI) Crohn's disease (CD) is uncommon and frequently presents nonspecifically, leading to diagnostic delay. We present, a 15-year-old adolescent boy with family history of ileal CD presented with nausea, vomiting, weight loss, and alternating diarrhea and constipation. Endoscopy with histology demonstrated isolated UGI CD. Advanced combination therapy with infliximab and upadacitinib was initiated. The patient's symptoms resolved and endoscopic mucosal improvement and histologic normalization occurred within four months. Following a taper of upadacitinib and continued infliximab, the patient remains in remission. This case supports use of advanced combination therapy for UGI CD.

PMID 43032779
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多infliximab